Concepts (335)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tablets | 98 | 2024 | 118 | 26.060 |
Why?
|
| Drug Compounding | 58 | 2024 | 78 | 17.080 |
Why?
|
| Excipients | 46 | 2024 | 49 | 15.520 |
Why?
|
| Powders | 70 | 2024 | 74 | 13.430 |
Why?
|
| Chemistry, Pharmaceutical | 41 | 2021 | 59 | 11.090 |
Why?
|
| Cellulose | 33 | 2020 | 55 | 8.300 |
Why?
|
| Crystallization | 44 | 2024 | 206 | 6.230 |
Why?
|
| Technology, Pharmaceutical | 22 | 2022 | 30 | 5.850 |
Why?
|
| Solubility | 38 | 2024 | 177 | 5.610 |
Why?
|
| Tensile Strength | 40 | 2024 | 79 | 5.340 |
Why?
|
| Stearic Acids | 10 | 2023 | 11 | 4.150 |
Why?
|
| Particle Size | 39 | 2024 | 122 | 3.960 |
Why?
|
| Pharmaceutical Preparations | 11 | 2020 | 92 | 3.900 |
Why?
|
| Lactose | 13 | 2019 | 27 | 3.730 |
Why?
|
| Berberine | 4 | 2023 | 8 | 3.200 |
Why?
|
| Surface-Active Agents | 5 | 2021 | 59 | 3.120 |
Why?
|
| Pressure | 18 | 2024 | 165 | 2.620 |
Why?
|
| Carbamazepine | 4 | 2020 | 10 | 2.610 |
Why?
|
| Silicon Dioxide | 8 | 2022 | 39 | 2.510 |
Why?
|
| Sodium Dodecyl Sulfate | 5 | 2021 | 25 | 2.470 |
Why?
|
| Porosity | 25 | 2022 | 60 | 2.430 |
Why?
|
| Lubricants | 4 | 2020 | 7 | 2.210 |
Why?
|
| Water | 14 | 2020 | 277 | 2.110 |
Why?
|
| Taste | 3 | 2020 | 28 | 2.080 |
Why?
|
| Drug Liberation | 10 | 2021 | 15 | 2.010 |
Why?
|
| Hardness | 15 | 2022 | 19 | 1.980 |
Why?
|
| Pyrazines | 3 | 2024 | 92 | 1.810 |
Why?
|
| Thiazines | 5 | 2020 | 5 | 1.800 |
Why?
|
| Ibuprofen | 6 | 2023 | 28 | 1.730 |
Why?
|
| Surface Properties | 15 | 2020 | 130 | 1.700 |
Why?
|
| Celecoxib | 7 | 2023 | 31 | 1.690 |
Why?
|
| X-Ray Diffraction | 15 | 2023 | 124 | 1.660 |
Why?
|
| Mannitol | 4 | 2019 | 49 | 1.640 |
Why?
|
| Drug Stability | 15 | 2022 | 48 | 1.610 |
Why?
|
| Pyrrolidines | 3 | 2023 | 58 | 1.590 |
Why?
|
| Flucytosine | 3 | 2016 | 11 | 1.510 |
Why?
|
| Drug Delivery Systems | 5 | 2022 | 178 | 1.500 |
Why?
|
| Biological Availability | 5 | 2024 | 92 | 1.450 |
Why?
|
| Piroxicam | 2 | 2020 | 11 | 1.410 |
Why?
|
| Coumaric Acids | 2 | 2019 | 6 | 1.400 |
Why?
|
| Glutarates | 2 | 2020 | 8 | 1.390 |
Why?
|
| Ritonavir | 2 | 2019 | 12 | 1.390 |
Why?
|
| Drug Carriers | 3 | 2020 | 82 | 1.370 |
Why?
|
| Administration, Oral | 10 | 2023 | 684 | 1.350 |
Why?
|
| Models, Chemical | 8 | 2018 | 178 | 1.310 |
Why?
|
| Acetaminophen | 4 | 2020 | 54 | 1.280 |
Why?
|
| Diphenhydramine | 2 | 2018 | 17 | 1.280 |
Why?
|
| Povidone | 4 | 2022 | 6 | 1.220 |
Why?
|
| Oxalic Acid | 2 | 2019 | 8 | 1.180 |
Why?
|
| Calcium Phosphates | 3 | 2017 | 77 | 1.150 |
Why?
|
| Nanoparticles | 6 | 2019 | 157 | 1.150 |
Why?
|
| Glucuronosyltransferase | 4 | 2014 | 184 | 1.150 |
Why?
|
| Citric Acid | 3 | 2018 | 38 | 1.150 |
Why?
|
| Physical Phenomena | 2 | 2023 | 7 | 1.140 |
Why?
|
| 4-Aminobenzoic Acid | 3 | 2024 | 6 | 1.140 |
Why?
|
| Polymers | 5 | 2020 | 202 | 1.120 |
Why?
|
| Antifungal Agents | 3 | 2016 | 117 | 1.090 |
Why?
|
| Helium | 2 | 2023 | 10 | 1.090 |
Why?
|
| Solvents | 4 | 2020 | 96 | 1.000 |
Why?
|
| Theophylline | 4 | 2019 | 34 | 0.990 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2016 | 46 | 0.950 |
Why?
|
| Humidity | 9 | 2023 | 89 | 0.950 |
Why?
|
| Salts | 2 | 2021 | 16 | 0.950 |
Why?
|
| Stress, Mechanical | 4 | 2019 | 248 | 0.930 |
Why?
|
| Emulsions | 2 | 2020 | 19 | 0.920 |
Why?
|
| Aspirin | 2 | 2022 | 156 | 0.880 |
Why?
|
| Emollients | 1 | 2022 | 2 | 0.860 |
Why?
|
| Gastric Juice | 1 | 2022 | 15 | 0.860 |
Why?
|
| Duodenum | 1 | 2022 | 100 | 0.820 |
Why?
|
| Compressive Strength | 8 | 2017 | 24 | 0.820 |
Why?
|
| Kinetics | 8 | 2019 | 1513 | 0.810 |
Why?
|
| Drug Industry | 2 | 2020 | 54 | 0.790 |
Why?
|
| Dicarboxylic Acids | 1 | 2021 | 22 | 0.790 |
Why?
|
| Wettability | 7 | 2019 | 7 | 0.780 |
Why?
|
| Calorimetry, Differential Scanning | 7 | 2023 | 12 | 0.770 |
Why?
|
| Allelic Imbalance | 2 | 2011 | 20 | 0.760 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2020 | 13 | 0.750 |
Why?
|
| Loratadine | 1 | 2020 | 21 | 0.750 |
Why?
|
| Parabens | 3 | 2019 | 4 | 0.740 |
Why?
|
| Diffusion | 4 | 2021 | 93 | 0.740 |
Why?
|
| Norfloxacin | 1 | 2019 | 5 | 0.730 |
Why?
|
| Sweetening Agents | 1 | 2020 | 17 | 0.730 |
Why?
|
| Vinyl Compounds | 2 | 2016 | 6 | 0.720 |
Why?
|
| Poloxamer | 1 | 2019 | 29 | 0.720 |
Why?
|
| Microscopy, Electron, Scanning | 7 | 2021 | 135 | 0.690 |
Why?
|
| Research Design | 1 | 2022 | 594 | 0.680 |
Why?
|
| Ionic Liquids | 1 | 2018 | 1 | 0.670 |
Why?
|
| Temperature | 8 | 2019 | 396 | 0.660 |
Why?
|
| Naproxen | 1 | 2018 | 13 | 0.650 |
Why?
|
| Fumarates | 1 | 2018 | 26 | 0.630 |
Why?
|
| Niacinamide | 3 | 2021 | 116 | 0.620 |
Why?
|
| Chemical Engineering | 1 | 2017 | 2 | 0.620 |
Why?
|
| Histamine H1 Antagonists | 1 | 2017 | 40 | 0.610 |
Why?
|
| Elastic Modulus | 3 | 2023 | 36 | 0.610 |
Why?
|
| Hardness Tests | 2 | 2015 | 3 | 0.610 |
Why?
|
| Models, Theoretical | 4 | 2019 | 482 | 0.600 |
Why?
|
| Powder Diffraction | 4 | 2023 | 4 | 0.570 |
Why?
|
| Hydrochloric Acid | 2 | 2016 | 11 | 0.570 |
Why?
|
| Algorithms | 3 | 2017 | 1830 | 0.550 |
Why?
|
| Succinic Acid | 1 | 2015 | 6 | 0.550 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 243 | 0.540 |
Why?
|
| Metformin | 1 | 2017 | 128 | 0.540 |
Why?
|
| Felodipine | 1 | 2014 | 2 | 0.510 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2022 | 493 | 0.510 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2014 | 2357 | 0.500 |
Why?
|
| Thermodynamics | 4 | 2019 | 309 | 0.490 |
Why?
|
| Chemical Precipitation | 4 | 2020 | 18 | 0.480 |
Why?
|
| Phase Transition | 4 | 2020 | 17 | 0.460 |
Why?
|
| Linkage Disequilibrium | 2 | 2011 | 473 | 0.440 |
Why?
|
| Molecular Structure | 5 | 2020 | 287 | 0.440 |
Why?
|
| Flurbiprofen | 1 | 2012 | 1 | 0.430 |
Why?
|
| Glass | 1 | 2011 | 15 | 0.420 |
Why?
|
| Vitamin B Complex | 1 | 2012 | 21 | 0.420 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2010 | 302 | 0.410 |
Why?
|
| Quality Control | 3 | 2020 | 117 | 0.400 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2011 | 267 | 0.390 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 92 | 0.390 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2011 | 45 | 0.390 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 3 | 2019 | 93 | 0.390 |
Why?
|
| Rheology | 5 | 2021 | 39 | 0.390 |
Why?
|
| Analgesics | 1 | 2012 | 119 | 0.390 |
Why?
|
| Climate | 1 | 2010 | 50 | 0.380 |
Why?
|
| Hypromellose Derivatives | 2 | 2020 | 4 | 0.370 |
Why?
|
| Materials Testing | 2 | 2019 | 91 | 0.370 |
Why?
|
| Adhesiveness | 2 | 2020 | 4 | 0.350 |
Why?
|
| Transition Temperature | 4 | 2016 | 9 | 0.340 |
Why?
|
| Sildenafil Citrate | 2 | 2020 | 22 | 0.330 |
Why?
|
| Adaptation, Physiological | 1 | 2010 | 306 | 0.320 |
Why?
|
| Liver | 2 | 2011 | 1228 | 0.320 |
Why?
|
| Biological Products | 2 | 2021 | 143 | 0.310 |
Why?
|
| Methylcellulose | 2 | 2019 | 6 | 0.310 |
Why?
|
| Alternative Splicing | 1 | 2009 | 201 | 0.310 |
Why?
|
| Biocompatible Materials | 1 | 2009 | 193 | 0.310 |
Why?
|
| Reproducibility of Results | 5 | 2020 | 2706 | 0.300 |
Why?
|
| Organic Chemicals | 1 | 2007 | 33 | 0.300 |
Why?
|
| Aspartame | 1 | 2006 | 5 | 0.290 |
Why?
|
| Gene Expression Regulation | 3 | 2010 | 1921 | 0.290 |
Why?
|
| Desiccation | 2 | 2019 | 6 | 0.280 |
Why?
|
| Elasticity | 2 | 2017 | 94 | 0.280 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 2903 | 0.270 |
Why?
|
| Models, Molecular | 5 | 2019 | 1286 | 0.260 |
Why?
|
| Curcumin | 2 | 2015 | 15 | 0.260 |
Why?
|
| Pyrazoles | 1 | 2006 | 153 | 0.250 |
Why?
|
| Databases, Factual | 2 | 2014 | 816 | 0.250 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2015 | 67 | 0.250 |
Why?
|
| Crystallography | 3 | 2021 | 45 | 0.250 |
Why?
|
| Acetazolamide | 1 | 2024 | 9 | 0.240 |
Why?
|
| Lubrication | 1 | 2023 | 2 | 0.240 |
Why?
|
| Sulfonamides | 1 | 2006 | 300 | 0.240 |
Why?
|
| Permeability | 2 | 2023 | 137 | 0.240 |
Why?
|
| Humans | 21 | 2024 | 86656 | 0.230 |
Why?
|
| X-Ray Microtomography | 1 | 2024 | 80 | 0.230 |
Why?
|
| Dipyridamole | 1 | 2023 | 14 | 0.230 |
Why?
|
| Proteins | 1 | 2009 | 777 | 0.230 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2023 | 245 | 0.230 |
Why?
|
| Pharmaceutical Research | 1 | 2022 | 2 | 0.220 |
Why?
|
| Chlorides | 1 | 2023 | 103 | 0.220 |
Why?
|
| Genotype | 4 | 2014 | 1852 | 0.220 |
Why?
|
| Genetic Variation | 1 | 2010 | 1351 | 0.220 |
Why?
|
| Hydrogen Bonding | 2 | 2021 | 144 | 0.210 |
Why?
|
| Carboxylic Acids | 1 | 2022 | 17 | 0.210 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2022 | 90 | 0.210 |
Why?
|
| Dry Powder Inhalers | 1 | 2021 | 3 | 0.210 |
Why?
|
| Mentors | 1 | 2022 | 76 | 0.200 |
Why?
|
| Chitosan | 2 | 2019 | 18 | 0.200 |
Why?
|
| Equipment Design | 3 | 2019 | 407 | 0.200 |
Why?
|
| Stomach | 1 | 2022 | 108 | 0.200 |
Why?
|
| Micelles | 2 | 2018 | 47 | 0.200 |
Why?
|
| Structure-Activity Relationship | 3 | 2019 | 408 | 0.190 |
Why?
|
| Gene Frequency | 3 | 2014 | 677 | 0.190 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 66 | 0.190 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 3 | 2021 | 30 | 0.190 |
Why?
|
| Dogs | 1 | 2021 | 686 | 0.190 |
Why?
|
| Flavoring Agents | 1 | 2020 | 7 | 0.190 |
Why?
|
| Binding Sites | 3 | 2019 | 1098 | 0.190 |
Why?
|
| Principal Component Analysis | 2 | 2018 | 155 | 0.190 |
Why?
|
| Animals | 6 | 2021 | 26590 | 0.180 |
Why?
|
| Regulatory-Associated Protein of mTOR | 2 | 2010 | 11 | 0.180 |
Why?
|
| Saccharin | 1 | 2020 | 8 | 0.180 |
Why?
|
| Nitrobenzoates | 1 | 2019 | 2 | 0.180 |
Why?
|
| Albendazole | 1 | 2019 | 4 | 0.180 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2018 | 315 | 0.180 |
Why?
|
| Least-Squares Analysis | 2 | 2017 | 48 | 0.180 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2010 | 133 | 0.180 |
Why?
|
| Talc | 1 | 2019 | 4 | 0.180 |
Why?
|
| Photoelectron Spectroscopy | 1 | 2019 | 2 | 0.180 |
Why?
|
| Sodium Chloride | 1 | 2019 | 88 | 0.170 |
Why?
|
| Muramidase | 1 | 2019 | 34 | 0.170 |
Why?
|
| Indomethacin | 1 | 2019 | 59 | 0.170 |
Why?
|
| Serum Albumin, Bovine | 1 | 2019 | 45 | 0.170 |
Why?
|
| Drug Storage | 1 | 2018 | 3 | 0.170 |
Why?
|
| Printing, Three-Dimensional | 1 | 2019 | 37 | 0.170 |
Why?
|
| Caffeine | 1 | 2019 | 81 | 0.170 |
Why?
|
| Breast | 2 | 2011 | 288 | 0.160 |
Why?
|
| Viscosity | 1 | 2017 | 46 | 0.160 |
Why?
|
| Crystallography, X-Ray | 2 | 2012 | 485 | 0.160 |
Why?
|
| Prevalence | 1 | 2021 | 1239 | 0.150 |
Why?
|
| Glucosides | 1 | 2017 | 20 | 0.150 |
Why?
|
| Benzhydryl Compounds | 1 | 2017 | 48 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 1221 | 0.150 |
Why?
|
| Adsorption | 1 | 2016 | 54 | 0.140 |
Why?
|
| Stilbenes | 1 | 2016 | 25 | 0.140 |
Why?
|
| Polyethylene Glycols | 2 | 2015 | 364 | 0.140 |
Why?
|
| Specific Gravity | 2 | 2005 | 3 | 0.140 |
Why?
|
| Sulfamerazine | 2 | 2005 | 2 | 0.140 |
Why?
|
| Polyvinyls | 1 | 2015 | 17 | 0.140 |
Why?
|
| Salvia miltiorrhiza | 1 | 2015 | 3 | 0.140 |
Why?
|
| Time Factors | 4 | 2019 | 5211 | 0.140 |
Why?
|
| Glyburide | 1 | 2015 | 32 | 0.130 |
Why?
|
| Pharmaceutic Aids | 1 | 2015 | 2 | 0.130 |
Why?
|
| Amlodipine | 1 | 2015 | 37 | 0.130 |
Why?
|
| Double-Blind Method | 1 | 2020 | 1824 | 0.130 |
Why?
|
| Friction | 1 | 2015 | 4 | 0.130 |
Why?
|
| Cell Line | 2 | 2011 | 2469 | 0.130 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2015 | 34 | 0.130 |
Why?
|
| Nanocapsules | 1 | 2015 | 11 | 0.130 |
Why?
|
| Heating | 1 | 2014 | 14 | 0.130 |
Why?
|
| Nanotechnology | 1 | 2015 | 68 | 0.130 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 185 | 0.120 |
Why?
|
| Rabbits | 1 | 2015 | 636 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 378 | 0.120 |
Why?
|
| Thermogravimetry | 1 | 2013 | 1 | 0.120 |
Why?
|
| Bayes Theorem | 1 | 2015 | 361 | 0.110 |
Why?
|
| Rats | 1 | 2020 | 3992 | 0.110 |
Why?
|
| Female | 6 | 2020 | 44547 | 0.110 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2012 | 23 | 0.110 |
Why?
|
| Molecular Conformation | 1 | 2012 | 96 | 0.100 |
Why?
|
| Protein Engineering | 1 | 2012 | 140 | 0.100 |
Why?
|
| HapMap Project | 1 | 2011 | 47 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2013 | 596 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2015 | 575 | 0.100 |
Why?
|
| Manufactured Materials | 1 | 2010 | 2 | 0.100 |
Why?
|
| Dosage Forms | 1 | 2010 | 7 | 0.100 |
Why?
|
| Alleles | 2 | 2014 | 1128 | 0.100 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2010 | 17 | 0.100 |
Why?
|
| Retinoids | 1 | 2010 | 17 | 0.100 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2010 | 15 | 0.100 |
Why?
|
| Retinoid X Receptors | 1 | 2010 | 39 | 0.100 |
Why?
|
| Transcription Initiation Site | 1 | 2010 | 45 | 0.100 |
Why?
|
| Hep G2 Cells | 1 | 2010 | 48 | 0.100 |
Why?
|
| Benzoates | 1 | 2010 | 44 | 0.100 |
Why?
|
| Mammography | 1 | 2014 | 463 | 0.090 |
Why?
|
| Computer Simulation | 1 | 2015 | 1078 | 0.090 |
Why?
|
| Geography | 1 | 2010 | 223 | 0.090 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2010 | 41 | 0.090 |
Why?
|
| Malonates | 1 | 2009 | 11 | 0.090 |
Why?
|
| Urea | 1 | 2009 | 58 | 0.090 |
Why?
|
| Dinucleotide Repeats | 1 | 2009 | 13 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2011 | 680 | 0.090 |
Why?
|
| Organ Specificity | 1 | 2010 | 258 | 0.090 |
Why?
|
| Haplotypes | 1 | 2011 | 642 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2010 | 506 | 0.080 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2009 | 268 | 0.080 |
Why?
|
| Drug Design | 1 | 2009 | 124 | 0.080 |
Why?
|
| Introns | 1 | 2009 | 289 | 0.080 |
Why?
|
| Young Adult | 1 | 2020 | 5980 | 0.080 |
Why?
|
| Research | 1 | 2009 | 253 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 853 | 0.080 |
Why?
|
| Genetics, Population | 1 | 2010 | 394 | 0.080 |
Why?
|
| Scattering, Radiation | 2 | 2019 | 114 | 0.080 |
Why?
|
| Selection, Genetic | 1 | 2011 | 502 | 0.070 |
Why?
|
| Protein Binding | 1 | 2010 | 1457 | 0.070 |
Why?
|
| Gene Expression | 1 | 2011 | 1284 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1807 | 0.070 |
Why?
|
| Light | 2 | 2019 | 289 | 0.070 |
Why?
|
| Stereoisomerism | 1 | 2006 | 102 | 0.070 |
Why?
|
| Male | 3 | 2022 | 40984 | 0.070 |
Why?
|
| Spectrum Analysis, Raman | 2 | 2021 | 15 | 0.070 |
Why?
|
| Mathematics | 1 | 2005 | 190 | 0.070 |
Why?
|
| Base Sequence | 1 | 2009 | 2330 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2426 | 0.060 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 90 | 0.060 |
Why?
|
| Chemistry, Physical | 1 | 2004 | 29 | 0.060 |
Why?
|
| Chemical Phenomena | 1 | 2004 | 72 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 3030 | 0.060 |
Why?
|
| Genome, Human | 1 | 2009 | 756 | 0.060 |
Why?
|
| Caco-2 Cells | 1 | 2023 | 123 | 0.060 |
Why?
|
| Intestinal Absorption | 1 | 2023 | 124 | 0.060 |
Why?
|
| Healthy Volunteers | 1 | 2024 | 143 | 0.060 |
Why?
|
| Academies and Institutes | 1 | 2023 | 31 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 1384 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2009 | 1981 | 0.060 |
Why?
|
| Linear Models | 1 | 2004 | 422 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 1673 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 2271 | 0.050 |
Why?
|
| Aerosols | 1 | 2021 | 44 | 0.050 |
Why?
|
| Chromatography, Gel | 1 | 2021 | 103 | 0.050 |
Why?
|
| Circular Dichroism | 1 | 2021 | 117 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2022 | 312 | 0.050 |
Why?
|
| Phenotype | 2 | 2020 | 2380 | 0.050 |
Why?
|
| Phospholipids | 1 | 2021 | 111 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 188 | 0.050 |
Why?
|
| Valproic Acid | 1 | 2021 | 24 | 0.050 |
Why?
|
| Pyrans | 1 | 2020 | 10 | 0.050 |
Why?
|
| Freezing | 1 | 2020 | 33 | 0.050 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2015 | 134 | 0.050 |
Why?
|
| Risk Factors | 1 | 2011 | 5420 | 0.050 |
Why?
|
| Adult | 1 | 2020 | 25657 | 0.050 |
Why?
|
| Materials Science | 1 | 2019 | 1 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2019 | 46 | 0.040 |
Why?
|
| Enzyme Stability | 1 | 2019 | 39 | 0.040 |
Why?
|
| Protein Unfolding | 1 | 2019 | 12 | 0.040 |
Why?
|
| Protein Aggregates | 1 | 2019 | 20 | 0.040 |
Why?
|
| Gelatin | 1 | 2019 | 25 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 77 | 0.040 |
Why?
|
| Static Electricity | 1 | 2019 | 89 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 55 | 0.040 |
Why?
|
| Proteolysis | 1 | 2019 | 100 | 0.040 |
Why?
|
| Cattle | 1 | 2019 | 376 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2019 | 248 | 0.040 |
Why?
|
| Protein Structure, Secondary | 1 | 2019 | 330 | 0.040 |
Why?
|
| Macrophages | 1 | 2020 | 557 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2017 | 116 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2019 | 736 | 0.040 |
Why?
|
| para-Aminobenzoates | 1 | 2016 | 4 | 0.040 |
Why?
|
| Models, Biological | 1 | 2023 | 1749 | 0.030 |
Why?
|
| Freeze Drying | 1 | 2015 | 14 | 0.030 |
Why?
|
| Biopharmaceutics | 1 | 2015 | 1 | 0.030 |
Why?
|
| Benzamides | 1 | 2016 | 229 | 0.030 |
Why?
|
| Camptothecin | 1 | 2015 | 189 | 0.030 |
Why?
|
| Fourier Analysis | 1 | 2014 | 125 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2015 | 989 | 0.030 |
Why?
|
| Multigene Family | 1 | 2014 | 202 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 315 | 0.030 |
Why?
|
| Neutrons | 1 | 2012 | 58 | 0.030 |
Why?
|
| Middle Aged | 1 | 2011 | 25036 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 294 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2014 | 840 | 0.020 |
Why?
|
| Capsules | 1 | 2010 | 38 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 155 | 0.020 |
Why?
|
| Software | 1 | 2014 | 654 | 0.020 |
Why?
|
| Choline | 1 | 2009 | 23 | 0.020 |
Why?
|
| Microscopy | 1 | 2009 | 87 | 0.020 |
Why?
|
| Microscopy, Atomic Force | 1 | 2005 | 52 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 819 | 0.020 |
Why?
|